International journal of infectious diseases and research最新文献

筛选
英文 中文
Anti-Tuberculosis Drugs and Mechanisms of Action: Review 抗结核药物及其作用机制综述
International journal of infectious diseases and research Pub Date : 2023-05-01 DOI: 10.47485/2693-2326.1028
{"title":"Anti-Tuberculosis Drugs and Mechanisms of Action: Review","authors":"","doi":"10.47485/2693-2326.1028","DOIUrl":"https://doi.org/10.47485/2693-2326.1028","url":null,"abstract":"Tuberculosis is the most important communicable disease in the world caused by the bacillus Mycobacterium tuberculosis. Mycobacterium is intrinsically resistant to most antibiotics and grows more slowly than other bacteria. Antibiotics are only active against rapidly growing bacterial cells. The cell wall of M. tuberculosis made up of lipid-rich polysaccharides, which are impermeable to many antibacterial agents as a result of poor penetration of drugs they develop resistance with increased level of antibiotic efflux and become Multiple Drug Resistance (MDRs). Prevention and quality diagnosis and treatment of MDR- and XDR-TB are part of the crucial interventions included in the new World Health Organization (WHO) End TB Strategy, which is focused on the goal of TB elimination program. Combinations of two or more drugs are used to overcome the obstacles to prevent emergence of resistance during the course of treatment. Based on drugs used for mycobacterial infections, treatment is administered for months to years. Anti-tuberculosis drugs are classified based on clinical response as first-line drugs and second-line drugs. First Line drugs with high anti-tubercular efficacy as well as low toxicity – routinely used Isoniazid (H), Rifampin (R), Pyrazinamide (Z), Isoniazid (H), Rifampin (R), Pyrazinamide (Z), Ethambutol (E), Streptomycin (S) – HRZES. Second Line drugs are with low anti-tubercular efficacy or high toxicity Paraminosalicylic Acid, Cycloserine, Kanamycin, Amikacin, Ciprofloxacin, Olfloxacin, Clarithromycin, and Azithromycin. Modes of action of majority of the anti-mycobacterial drugs either inhibit their cell wall synthesis or their protein synthesis. In spite of the limitations, the evidence accumulated in the last few years suggests that a new classification of the anti-TB drugs is necessary in the near future.","PeriodicalId":499211,"journal":{"name":"International journal of infectious diseases and research","volume":"56 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135517090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书